Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Division of Nephrology, Department of Internal Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.
Kidney Int. 2024 May;105(5):1049-1057. doi: 10.1016/j.kint.2024.01.036. Epub 2024 Feb 22.
Focal segmental glomerulosclerosis (FSGS) lesions have been linked to variants in COL4A3/A4/A5 genes, which are also mutated in Alport syndrome. Although it could be useful for diagnosis, quantitative evaluation of glomerular basement membrane (GBM) type IV collagen (colIV) networks is not widely used to assess these patients. To do so, we developed immunofluorescence imaging for collagen α5(IV) and α1/2(IV) on kidney paraffin sections with Airyscan confocal microscopy that clearly distinguishes GBM collagen α3α4α5(IV) and α1α1α2(IV) as two distinct layers, allowing quantitative assessment of both colIV networks. The ratios of collagen α5(IV):α1/2(IV) mean fluorescence intensities (α5:α1/2 intensity ratios) and thicknesses (α5:α1/2 thickness ratios) were calculated to represent the levels of collagen α3α4α5(IV) relative to α1α1α2(IV). The α5:α1/2 intensity and thickness ratios were comparable across all 11 control samples, while both ratios were significantly and markedly decreased in all patients with pathogenic or likely pathogenic Alport COL4A variants, supporting validity of this approach. Thus, with further validation of this technique, quantitative measurement of GBM colIV subtype abundance by immunofluorescence, may potentially serve to identify the subgroup of patients with FSGS lesions likely to harbor pathogenic COL4A variants who could benefit from genetic testing.
局灶节段性肾小球硬化症 (FSGS) 病变与 COL4A3/A4/A5 基因变异有关,这些基因在 Alport 综合征中也发生突变。虽然它可能有助于诊断,但定量评估肾小球基底膜 (GBM) 型 IV 型胶原 (colIV) 网络并不广泛用于评估这些患者。为此,我们开发了用于肾脏石蜡切片的胶原 α5(IV)和 α1/2(IV) 的免疫荧光成像,使用 Airyscan 共聚焦显微镜可以清楚地区分 GBM 胶原 α3α4α5(IV)和 α1α1α2(IV),形成两个不同的层,从而可以定量评估两种 colIV 网络。计算胶原 α5(IV):α1/2(IV)平均荧光强度 (α5:α1/2 强度比)和厚度 (α5:α1/2 厚度比)比值,以表示相对于 α1α1α2(IV)的 colIV 水平。11 个对照样本中所有样本的 α5:α1/2 强度和厚度比值均具有可比性,而所有致病性或可能致病性 Alport COL4A 变异患者的两种比值均显著且明显降低,支持该方法的有效性。因此,随着该技术的进一步验证,通过免疫荧光定量测量 GBM colIV 亚型的丰度,可能有助于识别出 FSGS 病变患者亚群,这些患者可能携带致病性 COL4A 变异,从而受益于基因检测。